References
- Chuenkitmongkol S, Solante R, Burhan E, et al. Expert review on global real-world vaccine effectiveness against SARS-CoV-2 Expert Review of Vaccines. [cited 2022 Jun 30]. 2022. Available from: https://doi.org/10.1080/14760584.2022.2092472 DOI: 10.1080/14760584.2022.2092472
- Chariyalertsak S, Intawong, K., Chalom, K, et al. Effectiveness of heterologous 3rd and 4th dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand. Research Square 2022. Preprint. [cited 2022 Jul]. Preprint https://doi.org/10.21203/rs.3.rs-1792139/v1
- Palacios R, Batista, A.P., Albuquerque, C.S.N, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil. The PROFISCOV Study. [cited 2022 Jul]. Available from: https://ssrn.com/abstract=3822780
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
- Polack FP, Thomas, S.J., Kitchin, N., et al. C4591001 clinical trial group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
- Mayr FB, Talisa VB, Shaikh O, et al. effectiveness of homologous or heterologous Covid-19 boosters in veterans. N Engl J Med. 2022;386(14):1375–1377.
- Accorsi EK, Britton A, Shang N, et al. Effectiveness of homologous and heterologous Covid-19 boosters against omicron. N Engl J Med. 2022 Jul;386(25):2433–2435.
- Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes Infect. 2022;11(1):585–592.
- Intawong K, Olson D, Chariyalertsak S, et al. Application technology to fight the COVID-19 pandemic: lessons learned in Thailand. Biochem Biophys Res Commun. 2021 January 1st;534:830–836.
- Tuekprakhon, Huo J, Nutalai R, et al. 200 bioRxiv preprint. DOI:10.1101/2022.05.21.492554
- Regev‑Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377–1380.